Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2024)

Allogene Therapeutics (ALLO) has disclosed EBITDA Margin for 4 consecutive years, with 295327.27% as the latest value for Q1 2024.

  • Quarterly EBITDA Margin rose 2459273.0% to 295327.27% in Q1 2024 from the year-ago period, while the trailing twelve-month figure was 1166927.27% through Dec 2024, down 83188096.0% year-over-year, with the annual reading at 1166927.27% for FY2024, 83188096.0% down from the prior year.
  • EBITDA Margin hit 295327.27% in Q1 2024 for Allogene Therapeutics, up from 401533.33% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2.75% in Q4 2021 to a low of 401533.33% in Q4 2023.
  • Historically, EBITDA Margin has averaged 230243.62% across 4 years, with a median of 276577.27% in 2023.
  • Biggest five-year swings in EBITDA Margin: crashed -36247032bps in 2022 and later skyrocketed 4093384bps in 2023.
  • Year by year, EBITDA Margin stood at 2.75% in 2021, then crashed by -13164303bps to 362473.08% in 2022, then decreased by -11bps to 401533.33% in 2023, then increased by 26bps to 295327.27% in 2024.
  • Business Quant data shows EBITDA Margin for ALLO at 295327.27% in Q1 2024, 401533.33% in Q4 2023, and 276577.27% in Q3 2023.